Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
News and updates for Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) focus on its activities in neurological and rare diseases, including commercial performance and clinical development. Company press releases highlight revenue trends from its marketed medicines NUPLAZID for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE for Rett syndrome, as well as guidance ranges for total revenues and net product sales.
Investors following ACAD news can see announcements of quarterly financial results, participation in major healthcare and investor conferences, and business updates presented at events such as the J.P. Morgan Healthcare Conference. These updates often describe how NUPLAZID and DAYBUE are performing commercially and how Acadia views the growth outlook for its neurology and neuro‑rare franchises.
Acadia’s news flow also covers regulatory and clinical milestones. Examples include U.S. Food and Drug Administration approval of DAYBUE STIX, a powder formulation of trofinetide for oral solution for Rett syndrome in adults and pediatric patients 2 years of age and older, approval of DAYBUE oral solution by the Ministry of Health in Israel, and progress toward regulatory opinions and late‑stage studies for trofinetide in other regions. The company issues updates on its pipeline, such as timelines for Phase 2 and Phase 3 trials of remlifanserin (ACP‑204) in Alzheimer’s disease psychosis and Lewy body dementia psychosis, and data presentations on ACP‑711 and NUPLAZID at scientific congresses.
Readers of this ACAD news page can use it to track Acadia’s financial disclosures, regulatory approvals, clinical trial readouts, and strategic commentary from management over time. The news archive provides context on how the company’s commercial portfolio and pipeline in central nervous system and neuro‑rare diseases are evolving.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced a scientific presentation on pimavanserin at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled for November 9-12, 2021, in Boston, MA. A poster presentation will summarize post-hoc analysis results from the Phase 3 HARMONY trial, focusing on treating hallucinations and delusions in patients with Parkinson’s disease dementia. Although pimavanserin is FDA-approved for Parkinson’s disease psychosis, it is not approved for dementia-related psychosis.
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) will participate in several upcoming virtual investor conferences, including the Citi’s 16th Annual BioPharma Virtual Conference on September 10, 2021, Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 13, 2021, and the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021. Live webcasts will be accessible on the company’s website under the investors section, with archived recordings available for a month post-event.
Acadia Pharmaceuticals (Nasdaq: ACAD) announced the departure of Elena Ridloff, Chief Financial Officer, effective September 10, 2021, as she transitions to another biopharmaceutical firm. Mark Schneyer, Senior VP of Business Development, will serve as interim CFO while a formal search for a new CFO is conducted. CEO Steve Davis expressed gratitude for Ridloff's contributions to Acadia's growth and the pimavanserin franchise.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced its participation in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 3:00 p.m. Eastern Time. The event will be held virtually, with a live webcast available on Acadia's website, www.acadia-pharm.com. An archived recording will be accessible until September 12, 2021. Acadia specializes in neuroscience, focusing on therapies for Parkinson's disease psychosis and exploring new treatments for dementia-related psychosis and other CNS disorders.
Acadia Pharmaceuticals (Nasdaq: ACAD) reported Q2 2021 financial results, with NUPLAZID sales reaching $115.2 million, a 5% increase year-over-year. The company is engaging with the FDA regarding pimavanserin for dementia-related psychosis after a recent Type A meeting. However, they face challenges in conducting further subgroup studies. R&D expenses decreased to $56.9 million, while SG&A expenses rose to $96.8 million. Acadia's net loss for Q2 was $43.9 million. Guidance for NUPLAZID sales has been reduced to $480-$515 million due to the pandemic impacting patient visits.
Acadia Pharmaceuticals announced positive results from the Phase 3 HARMONY study, published in the New England Journal of Medicine, evaluating pimavanserin for treating hallucinations and delusions in dementia-related psychosis (DRP). The study, involving 392 patients, showed a 2.8-fold reduction in relapse risk for those continuing pimavanserin compared to placebo (HR=0.35, p=0.005). Pimavanserin also proved well-tolerated with no cognitive decline. This represents a significant advancement in addressing an unmet need, as no FDA-approved treatments exist for DRP.
Acadia Pharmaceuticals (Nasdaq: ACAD) will release its second quarter 2021 financial results on August 4, 2021, after market close. A conference call is scheduled for the same day at 4:30 p.m. Eastern Time to discuss these results. Participants can access the call via dial-in numbers or through a live webcast available on Acadia's website. The company continues to focus on neuroscience breakthroughs, particularly in developing therapies for conditions such as dementia-related psychosis and schizophrenia, while also noting the risks associated with drug development.
Acadia Pharmaceuticals (Nasdaq: ACAD) announced three scientific presentations on dementia-related psychosis at the Alzheimer’s Association International Conference 2021, occurring July 26-30 in Denver and virtually.
The presentations include two studies on pimavanserin used alongside antidementia medications, focusing on safety outcomes and pharmacokinetic profiles. A third study will introduce a novel screening tool for psychosis in dementia.
These findings aim to enhance understanding and treatment strategies for patients with neurodegenerative conditions.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has published new data from an open-label extension study regarding the efficacy of NUPLAZID for treating hallucinations and delusions in patients with Parkinson’s disease psychosis (PDP). The study revealed sustained efficacy for patients previously on a 34 mg dose of NUPLAZID from Weeks 6 to 10. Approximately 50% of Parkinson’s patients may experience these troubling symptoms, which can significantly impact quality of life. The findings reinforce NUPLAZID's position as a critical first-line therapy for PDP.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced the publication of open-label extension (OLE) data showing sustained efficacy of NUPLAZID (34 mg) for treating hallucinations and delusions in Parkinson's disease psychosis (PDP). Patients previously on lower doses demonstrated improvement after switching to NUPLAZID. The OLE study involved 459 patients, of which 424 were assessed, revealing significant symptom improvements. Adverse events were reported by 46.8% of patients, mostly mild, with some serious cases. This data reinforces NUPLAZID's role as a first-line therapy for PDP.